Table 1.

Characteristics and treatment of patients receiving PO and IV cyclophosphamide

	PO cyclophosphamide group N (%)	IV cyclophosphamide group N (%)	P value for difference between groups
Age (median, IQR)	72 (65–78)	55 (44–68)	< 0.0001*
Male	28 (49%)	31 (54%)	0.57
PR3-ANCA	22 (39%)	35 (61%)	0.02*
MPO-ANCA	32 (56%)	17 (30%)
ANCA negative	3 (5%)	5 (9%)
Renal involvement	56 (98%)	26 (46%)	< 0.001*
ENT involvement	9 (16%)	33 (58%)	< 0.001*
Neurological involvement	2 (4%)	19 (33%)	< 0.001*
Eye involvement	0	5 (9%)	0.02*
Abdominal involvement	0	6 (11%)	0.01*
General/systemic involvement	18 (32%)	27 (47%)	0.09
Cutaneous involvement	5 (9%)	9 (16%)	0.25
Pulmonary involvement	23 (40%)	25 (46%)	0.57
Cardiovascular involvement	2 (4%)	2 (4%)	1.0
Serum creatinine	295 (158–618)	80 (68–100)	< 0.0001*
Plasma exchange	24 (42%)	8 (14%)	0.001*
Refractory disease	1 (2%)	2 (4%)	0.5
Follow-up time (years)	4.0 (2.6–6.7)	5.1 (3.2–7.6)	0.10
Prednisolone dose at diagnosis	45 (30–60)	60 (42.5–60)	0.06
Prednisolone dose at 3 months	15 (15–20)	15 (10–20)	0.15
Prednisolone dose at 6 months	10 (7.5–10)	7.5 (5–10)	0.10
Prednisolone dose at 1 year	5 (5–7.5)	5 (2.5–7.5)	0.15
Creatinine at 5 years	142 (76–206)	86 (76–107)	< 0.0001*

*P value significant at 95% confidence level